For the quarter ending 2025-09-30, CRVS made $11,398K in revenue. -$10,069K in net income. Net profit margin of -88.34%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 8,454 | 7,873 | ||
| General and administrative | 2,118 | 2,387 | ||
| Total operating expenses | 10,572 | 10,260 | ||
| Loss from operations | -10,572 | -10,260 | ||
| Interest income and other expense, net | 738 | 639 | ||
| Change in fair value of warrant liability | - | -2,012 | ||
| Loss before equity method investment | -9,834 | -7,609 | ||
| Loss from equity method investment | -323 | -389 | ||
| Net loss | -10,157 | -7,998 | ||
| Unrealized gain (loss) on marketable securities | 29 | -19 | ||
| Cumulative foreign currency translation adjustment | 59 | 125 | ||
| Comprehensive loss | -10,069 | -7,892 | ||
| Earnings per share, basic | -0.12 | -0.1 | ||
| Earnings per share, diluted | -0.12 | -0.1 | ||
| Weighted average number of shares outstanding, basic | 82,836,369 | 77,774,344 | ||
| Weighted average number of shares outstanding, diluted | 82,836,369 | 77,774,344 | ||
Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS)